The Goldman Sachs Group, Inc. 13D and 13G filings for Silexion Therapeutics Ltd.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-05-13 11:36 am Purchase |
2025-03-31 | 13G | Silexion Therapeutics Ltd. SLXN |
GOLDMAN SACHS GROUP INC GS |
211,945 2.400% |
99,703 (+88.83%) |
Filing |
| 2025-02-10 5:31 pm Purchase |
2024-12-31 | 13G | Silexion Therapeutics Ltd. SLXN |
GOLDMAN SACHS GROUP INC GS |
112,242 6.600% |
112,242 (New Position) |
Filing |